Pacific Edge (CY3) Stock Overview

A cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. More details

CY3 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 41.31% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

CY3 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Pacific Edge Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pacific Edge
Historical stock prices
Current Share Price	NZ$0.14
52 Week High	NZ$0.17
52 Week Low	NZ$0.076
Beta	0.84
1 Month Change	8.18%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	59.26%

Recent updates

Shareholder Returns

	CY3	DE Biotechs	DE Market
7D	-18.7%	0.2%	2.4%
1Y	n/a	-5.0%	5.0%

Return vs Industry: Insufficient data to determine how CY3 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how CY3 performed against the German Market.

Price Volatility

Is CY3's price volatile compared to industry and market?
CY3 volatility
CY3 Average Weekly Movement	19.9%
Biotechs Industry Average Movement	9.0%
Market Average Movement	5.9%
10% most volatile stocks in DE Market	13.2%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: CY3's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine CY3's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	n/a	Peter Meintjes	www.pacificedgedx.com

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer.

Pacific Edge Limited Fundamentals Summary

How do Pacific Edge's earnings and revenue compare to its market cap?
CY3 fundamental statistics
Market cap	€179.20m
Earnings (TTM)	-€17.94m
Revenue (TTM)	€6.52m

27.5x

P/S Ratio

-10.0x

P/E Ratio

Is CY3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CY3 income statement (TTM)
Revenue	NZ$13.01m
Cost of Revenue	NZ$11.61m
Gross Profit	NZ$1.41m
Other Expenses	NZ$37.18m
Earnings	-NZ$35.78m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.031
Gross Margin	10.81%
Net Profit Margin	-274.96%
Debt/Equity Ratio	0%

How did CY3 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/17 11:07
End of Day Share Price	2026/06/17 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pacific Edge Limited is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	Brookline Capital Markets
Maxim Jacobs	Edison Investment Research
Benjamin Crozier	Forsyth Barr Group Ltd.

Pacific Edge LimitedDB:CY3 Stock Report